Johns Hopkins University to open cancer research center with $125 million in donations

Johns Hopkins University in Baltimore has launched the Bloomberg-Kimmel Institute for Cancer Immunotherapy, an institute entirely devoted to researching cancer treatment, with $125 million in donations.

The institute was started with two $50 million donations, one from former New York City mayor Michael R. Bloomberg and the other from philanthropist Sidney Kimmel.

Vice President Joe Biden, who famously spread word of the Obama administration’s “moonshot” to end cancer back in January, spoke at the institute's dedication.

“This institute is going to perfect new therapies and bring hope to millions of people,” Biden said, as quoted by Johns Hopkins in a statement. “I'm convinced, not only will we save millions of lives, we will re-instill in the American public the notion that anything is possible.”

According to another Johns Hopkins statement, the funds will be used primarily for research, but will also help recruit scientists, provide infrastructure, and “enhance partnerships with the private sector.”

“We believe the focused and collaborative research made possible through the Bloomberg–Kimmel Institute for Cancer Immunotherapy will advance immunotherapies to the point where the immune system will ultimately be able to beat 100 percent of cancers,” Drew Pardoll, MD, PhD, the institute's director, said in the statement. “The potential to control or cure even the most advanced, treatment-resistant cancers has been elusive until now.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.